Supplementum 298: Abstracts of the joint annual meeting of the Swiss Society of Cardiology (SSC), the Swiss Society for Heart and Thoracic Vascular Surgery (SSCS), the Swiss Society of Pneumology (SSP) and the Swiss Society for Thoracic Surgery (SSTS): Basel, Switzerland, June 10-12, 2026 - Orals SSC and SSCS

Swiss Society of Cardiology; Swiss Society for Heart and Thoracic Vascular Surgery

doi:10.57187/5576

June 3, 2026Swiss Medical WeeklyOpen Access

Supplementum 298: Abstracts of the joint annual meeting of the Swiss Society of Cardiology (SSC), the Swiss Society for Heart and Thoracic Vascular Surgery (SSCS), the Swiss Society of Pneumology (SSP) and the Swiss Society for Thoracic Surgery (SSTS): Basel, Switzerland, June 10-12, 2026 - Orals SSC and SSCS

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Does mavacamten improve NYHA class and reduce LVOTG in patients with obstructive hypertrophic cardiomyopathy?

Key Points

To present oral abstracts from the joint annual meeting of Swiss cardiology, pneumology, and thoracic surgery societies detailing translational mechanisms and clinical therapeutics.
Translational investigations performed single-nucleus RNA sequencing and secretome proteomics in models of heart failure with preserved ejection fraction and pulmonary hypertension.
Clinical evaluations included a multicenter Swiss cohort assessing mavacamten in hypertrophic obstructive cardiomyopathy and a systematic review with meta-analysis evaluating renin-angiotensin-aldosterone system blockade in dialysis-dependent heart failure.
Translational findings revealed that activated myofibroblasts, AP-1 complex upregulation (c-Fos, c-Jun), and CSF2 secretion promote microvascular injury, autophagy suppression, and myeloid reprogramming.
In the SWISS-MAVA cohort (N=82), mavacamten resulted in a Valsalva LVOTG <30 mmHg in 79.3% and NYHA class improvement in 86.6%, with transient LVEF reductions <50% occurring at an incidence of 5.9/100 patient-years.
In dialysis-dependent heart failure with reduced ejection fraction, meta-analyses showed significant reductions in all-cause mortality with ARNIs (HR 0.78, 95% CI 0.71–0.87) and ACEi/ARBs (HR 0.56, 95% CI 0.34–0.92), but no significant reduction in cardiovascular mortality (ARNI HR 0.84, 95% CI 0.57–1.24; ACEi/ARB HR 0.57, 95% CI 0.32–1.02).

Structured PICO

Does mavacamten improve NYHA class and reduce LVOTG in patients with obstructive hypertrophic cardiomyopathy?

P

Population

82 consecutive patients with obstructive hypertrophic cardiomyopathy (oHCM) treated with mavacamten across 4 Swiss referral centers. At baseline, 47/82 patients (57%) were in NYHA class III.

I

Intervention

Mavacamten

O

Outcome

Changes in New York Heart Association (NYHA) class and left ventricular outflow tract gradients (LVOTG)surrogate

Abstract

No abstract yet. The journal hasn't published one we can show.

Key Points

Structured PICO

Abstract

Discussion

Cite This Study

Key Points

Structured PICO

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Swiss Medical Weekly

Keep reading

More related papers

More from Swiss Medical Weekly